{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T21:00:10Z","timestamp":1792184410200,"version":"4.4.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"am","delay-in-days":411,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.euo.2025.06.004","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T15:08:13Z","timestamp":1754406493000},"page":"1087-1093","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Outcomes for [177Lu]Lu-PSMA-617 with and Without Concurrent Use of Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration-resistant Prostate Cancer"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7268-5077","authenticated-orcid":false,"given":"Miguel","family":"Muniz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Sartor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob J.","family":"Orme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina M.","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Scharf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth I.","family":"Heath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jabra G.","family":"Zarka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam M.","family":"Kase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irbaz B.","family":"Riaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack R.","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Thorpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Tuba Kendi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gokce Belge","family":"Bilgin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey B.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene D.","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.","family":"Childs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.06.004_b0005","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","article-title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","volume":"13","author":"Fizazi","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.06.004_b0010","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.06.004_b0015","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.06.004_b0020","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.euo.2025.06.004_b0025","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.06.004_b0030","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2025.06.004_b0035","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","article-title":"Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial","volume":"25","author":"Hofman","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.06.004_b0040","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S1470-2045(24)00440-6","article-title":"Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study","volume":"25","author":"Azad","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.06.004_b0045","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","article-title":"[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial","volume":"25","author":"Emmett","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.06.004_b0050","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1470-2045(25)00009-9","article-title":"Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial","volume":"26","author":"Emmett","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.06.004_b0055","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","article-title":"Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study","volume":"22","author":"Gafita","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.06.004_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102862","article-title":"Multivariable models of outcomes with [177Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial","volume":"77","author":"Herrmann","year":"2024","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.euo.2025.06.004_b0065","first-page":"1932","article-title":"Outcomes for patients with metastatic castration-resistant prostate cancer and liver metastasis receiving [177Lu]Lu-PSMA-617","volume":"65","author":"Muniz","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.euo.2025.06.004_b0070","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/pros.22910","article-title":"Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer","volume":"75","author":"Murga","year":"2015","journal-title":"Prostate"},{"key":"10.1016\/j.euo.2025.06.004_b0075","doi-asserted-by":"crossref","first-page":"950","DOI":"10.2967\/jnumed.118.223099","article-title":"Rapid modulation of PSMA expression by androgen deprivation: serial (68)Ga-PSMA-11 PET in men with hormone-sensitive and castrate-resistant prostate cancer commencing androgen blockade","volume":"60","author":"Emmett","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.euo.2025.06.004_b0080","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.eururo.2019.06.030","article-title":"Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer","volume":"76","author":"Paschalis","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.06.004_b0085","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.3390\/cancers14071696","article-title":"Upregulation of PSMA expression by enzalutamide in patients with advanced mCRPC","volume":"14","author":"Rosar","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.euo.2025.06.004_b0090","first-page":"S277","article-title":"Dynamic change in tumour PSMA expression between baseline and day 15 after commencing enzalutamide in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): findings from the randomised, phase 2, ENZA-p trial (ANZUP 1901)","volume":"51","author":"Emmett","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.euo.2025.06.004_b0095","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41585-024-00900-z","article-title":"Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer","volume":"22","author":"Bakht","year":"2025","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euo.2025.06.004_b0100","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","article-title":"PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial","volume":"23","author":"Buteau","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.06.004_b0105","doi-asserted-by":"crossref","first-page":"904","DOI":"10.2967\/jnumed.123.267014","article-title":"Development of a visually calculated SUVmean (HIT Score) on screening PSMA PET\/CT to predict treatment response to 177Lu-PSMA therapy: comparison with quantitative SUVmean and patient outcomes","volume":"65","author":"Swiha","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.euo.2025.06.004_b0110","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.233460","article-title":"Quantitative 68Ga-PSMA-11 PET and clinical outcomes in metastatic castration-resistant prostate cancer following 177Lu-PSMA-617 (VISION Trial)","volume":"312","author":"Kuo","year":"2024","journal-title":"Radiology"},{"key":"10.1016\/j.euo.2025.06.004_b0115","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","article-title":"Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer","volume":"381","author":"de Wit","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.06.004_b0120","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.06.004_b0125","doi-asserted-by":"crossref","first-page":"S1256","DOI":"10.1016\/j.annonc.2024.08.2310","article-title":"LBA67 cabozantinib (C) plus atezolizumab (A) versus 2nd novel hormonal therapy (NHT) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC): final overall survival (OS) results of the phase III, randomized, CONTACT-02 study","volume":"35","author":"Agarwal","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2025.06.004_b0130","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1200\/JCO.2025.43.5_suppl.121","article-title":"Efficacy of 177Lu-PSMA-617 with or without ARPIs for the treatment of mCRPC: VISION secondary analysis","volume":"43","author":"Yazdanpanah","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125001750?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125001750?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T19:26:35Z","timestamp":1762629995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125001750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2588931125001750"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.06.004","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes for [177Lu]Lu-PSMA-617 with and Without Concurrent Use of Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration-resistant Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}